SG10201809947UA - Use of prg4 as an anti-inflammatory agent - Google Patents

Use of prg4 as an anti-inflammatory agent

Info

Publication number
SG10201809947UA
SG10201809947UA SG10201809947UA SG10201809947UA SG10201809947UA SG 10201809947U A SG10201809947U A SG 10201809947UA SG 10201809947U A SG10201809947U A SG 10201809947UA SG 10201809947U A SG10201809947U A SG 10201809947UA SG 10201809947U A SG10201809947U A SG 10201809947UA
Authority
SG
Singapore
Prior art keywords
prg4
inflammatory
inflammatory agent
pro
lubricin
Prior art date
Application number
SG10201809947UA
Inventor
Tannin Avery Schmidt
Roman Krawetz
Jawed Fareed
Khaled Elsaid
Edward R Truitt
Gregory Jay
Benjamin D Sullivan
Adam Chodobski
Joanna Szmydynger-Chodobska
Original Assignee
Lubris Llc
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lubris Llc, Rhode Island Hospital filed Critical Lubris Llc
Publication of SG10201809947UA publication Critical patent/SG10201809947UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)

Abstract

USE OF PRG4 AS AN ANTI-INFLAMMATORY AGENT Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to 5 reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF- ț B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens. 10 [No suitable figure]
SG10201809947UA 2015-01-26 2016-01-26 Use of prg4 as an anti-inflammatory agent SG10201809947UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562107799P 2015-01-26 2015-01-26
US201562273059P 2015-12-30 2015-12-30

Publications (1)

Publication Number Publication Date
SG10201809947UA true SG10201809947UA (en) 2018-12-28

Family

ID=55361962

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201705636SA SG11201705636SA (en) 2015-01-26 2016-01-26 Use of prg4 as an anti-inflammatory agent
SG10201809947UA SG10201809947UA (en) 2015-01-26 2016-01-26 Use of prg4 as an anti-inflammatory agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201705636SA SG11201705636SA (en) 2015-01-26 2016-01-26 Use of prg4 as an anti-inflammatory agent

Country Status (21)

Country Link
US (2) US10967048B2 (en)
EP (2) EP3718559A1 (en)
JP (2) JP6758299B2 (en)
KR (1) KR20170123619A (en)
CN (2) CN113908257A (en)
AU (2) AU2016211694B2 (en)
BR (1) BR112017015310A8 (en)
CA (1) CA2972817A1 (en)
CL (2) CL2017001893A1 (en)
EA (1) EA036291B1 (en)
ES (1) ES2808199T3 (en)
HK (1) HK1247834A1 (en)
IL (2) IL253596B (en)
MA (1) MA53108A (en)
MX (1) MX2017009723A (en)
PH (1) PH12017501323A1 (en)
RU (1) RU2017129880A (en)
SG (2) SG11201705636SA (en)
TN (1) TN2017000270A1 (en)
WO (1) WO2016123123A1 (en)
ZA (1) ZA201705378B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
WO2015081121A1 (en) 2013-11-26 2015-06-04 Lubris Llc Compositions and methods for inhibiting intercellular interactions
KR20170123619A (en) 2015-01-26 2017-11-08 루브리스 엘엘씨 Uses of PRG4 as an anti-inflammatory agent
WO2016179085A1 (en) 2015-05-01 2016-11-10 Gentex Corporation Helmet impact attenuation article
WO2016187414A1 (en) 2015-05-19 2016-11-24 Lubris Llc Use of prg4 to improve dynamic visual acuity and higher order aberrations
CN106215170A (en) * 2016-08-23 2016-12-14 重庆医科大学 Interleukin Ⅲ 6 α treats in preparation, diagnoses or prevent the purposes in medication for treating pyemia
WO2018217919A1 (en) 2017-05-23 2018-11-29 Harmony Development Group, Inc. Tethered implantable device having an apical base plate with a hydraulic intracardiac adjusting mechanism
WO2019006152A1 (en) 2017-06-28 2019-01-03 Harmony Development Group, Inc. A force transducting inflatable implant system including a dual force annular transduction implant
WO2019173385A1 (en) 2018-03-05 2019-09-12 Harmony Development Group, Inc. A force transducting implant system for the mitigation of atrioventricular pressure gradient loss and the restoration of healthy ventricular geometry
CN108795867A (en) * 2018-06-05 2018-11-13 华东理工大学 The method for shifting external threedimensional model for building colon cancer cell peritonaeum
EP3810181A4 (en) * 2018-06-21 2022-03-30 Lubris LLC Lubricin for use in wound healing
CN109125709B (en) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Application of TRAIL mutant in preparation of medicine for treating acne and preparation
CN109620952A (en) * 2019-01-04 2019-04-16 北京中台恒基生物技术有限公司 A kind of tumor vaccine and preparation method thereof
US20220298234A1 (en) * 2019-05-13 2022-09-22 The Johns Hopkins University Macrophage diversity in regenerative, fibrotic biomaterial environments
JP2022534724A (en) * 2019-06-03 2022-08-03 ルブリス，エルエルシー． Use of PRG4 to treat cancer
US20230256052A1 (en) * 2020-07-07 2023-08-17 University Of Connecticut Method and composition for reducing or preventing bone resorption
IT202000022636A1 (en) * 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “COMBINATION THERAPY OF SORAFENIB AND/OR REGORAFENIB WITH THE RECOMBINANT HUMAN PROTEOGLYCAN-4 PROTEIN FOR THE TREATMENT OF HEPATOCARCINOMA”
CN114184792B (en) * 2021-11-17 2024-05-28 中国人民解放军总医院第二医学中心 Coronary heart disease marker IL-29 and application thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433142B1 (en) 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US7001881B1 (en) 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US20020006665A1 (en) 2000-04-05 2002-01-17 D'elia John Ketogulonigenium endogenous plasmids
US7415381B2 (en) 2003-01-09 2008-08-19 Rhode Island Hospital, A Lifespan Partner Joint friction sensing
US20060240037A1 (en) 2003-06-04 2006-10-26 Edward Fey Methods and compositions for the treatment and prevention of degenerative joint disorders
ES2388970T3 (en) * 2003-08-14 2012-10-22 Wyeth Llc Recombinant lubricin molecules and uses thereof
US20090155200A1 (en) 2004-04-20 2009-06-18 Jay Gregory D Methods of promoting cartilage healing or cartilage integration
CA2575086A1 (en) 2004-07-23 2006-02-02 Mucosal Therapeutics Llc Compositions and methods for viscosupplementation
US20080139458A1 (en) 2004-12-03 2008-06-12 Jay Gregory D Methods of Treatment For Injured or Diseased Joints
US20070111327A1 (en) 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
CN101077887A (en) * 2006-05-23 2007-11-28 中国医学科学院血液学研究所 Human accelerated haematogenous cell proliferated cytokine, preparation method and use thereof
UY30776A1 (en) 2006-12-21 2008-07-03 Medarex Inc CD44 ANTIBODIES
WO2008143816A1 (en) 2007-05-15 2008-11-27 Mucosal Therapeutics Compositions and methods for reducing friction between the surface of tendons or other soft tissues
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
US20090191287A1 (en) 2008-01-29 2009-07-30 Johnson W Dudley Mitigation of Inflammation-Related Injuries
RU2510274C2 (en) 2008-05-07 2014-03-27 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Therapeutic recovery and enhancement of ocular surface wetting
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
CN102438645A (en) * 2009-01-13 2012-05-02 卢布里斯有限责任公司 Therapeutic modulation of vaginal epithelium boundary lubrication
WO2010135736A2 (en) 2009-05-22 2010-11-25 Singularis Inc. Application and uses of prg4 and therapeutic modulation thereof
ES2634505T3 (en) 2009-08-13 2017-09-28 Lubris Llc PRG4 treatment for interstitial cystitis
EP2525805B1 (en) 2010-01-19 2017-03-15 Lubris LLC Oral care compositions and methods
US20130116186A1 (en) 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
US20150361452A1 (en) * 2013-01-25 2015-12-17 Baylor College Of Medicine A Helper-Dependent Adenoviral Gene Therapy Delivery and Expression System
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
WO2015081121A1 (en) 2013-11-26 2015-06-04 Lubris Llc Compositions and methods for inhibiting intercellular interactions
US20180161393A1 (en) 2015-01-26 2018-06-14 Lubris Llc Prg4 for treating gout and its symptoms
KR20170123619A (en) 2015-01-26 2017-11-08 루브리스 엘엘씨 Uses of PRG4 as an anti-inflammatory agent
WO2016187414A1 (en) 2015-05-19 2016-11-24 Lubris Llc Use of prg4 to improve dynamic visual acuity and higher order aberrations
US20170312335A1 (en) 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation

Also Published As

Publication number Publication date
JP7212653B2 (en) 2023-01-25
MX2017009723A (en) 2018-08-15
US11717557B2 (en) 2023-08-08
IL253596B (en) 2021-08-31
KR20170123619A (en) 2017-11-08
IL253596A0 (en) 2017-09-28
CL2017001893A1 (en) 2018-06-15
TN2017000270A1 (en) 2018-10-19
EP3250221B1 (en) 2020-05-27
MA53108A (en) 2021-05-12
AU2022200812A1 (en) 2022-02-24
CL2018003302A1 (en) 2019-01-04
CN107847556A (en) 2018-03-27
EA201791688A8 (en) 2018-05-31
AU2016211694B2 (en) 2021-11-11
ZA201705378B (en) 2020-11-25
WO2016123123A1 (en) 2016-08-04
PH12017501323A1 (en) 2018-02-05
BR112017015310A2 (en) 2018-01-16
BR112017015310A8 (en) 2021-02-23
US10967048B2 (en) 2021-04-06
EA201791688A1 (en) 2018-01-31
RU2017129880A3 (en) 2019-08-22
US20180015141A1 (en) 2018-01-18
JP2018505867A (en) 2018-03-01
CN107847556B (en) 2021-09-24
JP2020189878A (en) 2020-11-26
RU2017129880A (en) 2019-03-04
CN113908257A (en) 2022-01-11
US20210299214A1 (en) 2021-09-30
ES2808199T3 (en) 2021-02-25
EP3250221A1 (en) 2017-12-06
EP3718559A1 (en) 2020-10-07
IL285553A (en) 2021-09-30
HK1247834A1 (en) 2018-10-05
AU2016211694A1 (en) 2017-08-31
SG11201705636SA (en) 2017-08-30
JP6758299B2 (en) 2020-09-23
CA2972817A1 (en) 2016-08-04
EA036291B1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
SG10201809947UA (en) Use of prg4 as an anti-inflammatory agent
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
PH12018502634A1 (en) Topical compositions of apremilast
MX2016007111A (en) Inhibitors of bruton's tyrosine kinase.
MX2015009105A (en) Solid solution compositions and use in chronic inflammation.
MY180910A (en) Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
TW201613636A (en) Methods of treating Alzheimer's Disease
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MX2015009045A (en) Compositions and methods for treating severe pain.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
ZA201808086B (en) Method of treating diseases
MX2013011421A (en) Pyrazolo pyrimidine derivatives.
MX2017013564A (en) Glucopyranosyl lipid a and peanut allergen formulations for sublingual administration.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
IL286268A (en) Pridopidine for use in the treatment of mitochondrial associated diseases and disorders, including symptoms thereof
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
MX2019000677A (en) B-cell-mimetic cells.
JP2016513650A5 (en)
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
MX2016005976A (en) Storage stable lyophilized tripeptide formulations.
WO2016149382A3 (en) Compositions and methods for suppressing or reducing systemic immune response in a subject
GB201117490D0 (en) Anti-inflammatory compounds
MX2016011706A (en) Progesterone formulations.